Live updates

Outbreak of Norovirus confirmed at New Cross Hospital

An outbreak of Norovirus has been confirmed on four wards at New Cross Hospital in Wolverhampton.

One of the wards is closed to new patients. The movement of staff and patients currently on the ward have been restricted to prevent further spread of the Norovirus.

None of the patients are seriously unwell from the outbreak. Some staff have been affected and have been excluded from work until they are well.

New Cross Hospital in Wolverhampton
New Cross Hospital in Wolverhampton Credit: David Jones/PA

There have been Norovirus outbreaks and cases reported in the community.

We hope that the early detection and our actions will prevent spread to other wards. Scrupulous hand hygiene by all staff and visitors and a high level of environmental cleanliness are the essential measures for controlling this bug.

We have restricted the times of visiting and the number of visitors patients will be allowed to have on the affected wards, as this is a highly contagious disease. We hope that patients, relatives and carers understand the reasons for this restriction. Any visitors must decontaminate their hands properly before they leave the ward.

– Dr Mike Cooper, Director of Infection Prevention and Control for The Royal Wolverhampton NHS Trust,

Cricketers to learn life-saving skills in Loughborough

Photo of Joe Humphries.
The Joe Humphries Memorial Trust was set up in memory of the 14-year-old to raise awareness about SADS (sudden arrhythmic death syndrome) Credit: Family photo

England's under-19 cricket players will be at Loughborough University today learning some vital life-saving skills.

They will be taught how to put someone in the recovery position, CPR, what to do if someone has a cardiac arrest and how to use a defibrillator.

The skills will be delivered by the local charity Joe Humphries Memorial Trust.

Advertisement

Ten-year-old's father delighted with his post-op progress

The father of Ben Baddeley, a ten-year-old with cerebral palsy from Silverdale in Staffordshire, has described his son as 'like a different child'.

Ben who has cerebral palsy is attending a rehabilitation centre this weekend after a major operation to help him walk without pain.

Ben's family raised thousands of pounds to pay for the surgery after it was cancelled by the NHS due to funding cuts.

He will be taking part in body strengthening and physio sessions to help re-build his muscles.

Cancer drug's price makes it 'impossible' to support

The National Institute for Health and Care Excellence (Nice) has spoken of their 'disappointment' at not being able to recommend a breast cancer drug which can extend the life of terminal patients for up to 6 months.

Even with the extra flexibility that we can apply to cancer drugs, the price that Roche, the manufacturer are charging, makes it impossible to make that positive recommendation to the NHS.

– Andrew Dillon, Chief Executive of Nice

'Things have improved' at Peterborough care home

A care home in Peterborough where inspectors found people were left in 'beds of urine', has responded to a highly critical report by the Care Quality Commission.

A statement on behalf of Werrington Lodge, said:

We were made aware of these findings in May and June and we took immediate action. We were deeply concerned that the home was below the standards we expect for our residents.

We have made investment in a number of areas including training for current staff and adding more staff to the team. This includes additional nurses on the team, a senior nurse supervising each shift, plus daily support from our most senior and specialist staff.

We have also transformed the environment with refurbishments. Since the inspections in May and June we know we have made progress and this has been recognised by external parties involved - the Care Quality Commission and the Council.

Everyone is dedicated to providing the best possible care and we know things have improved and continue to improve. We would like to thank residents and relatives for their continued support.

National

Breast cancer drug manufacturer 'could have done more'

The manufacturer of a breast cancer drug that offers a last hope to patients could have been "more flexible" to help make the drug affordable for the NHS, a health service boss said.

Sir Andrew Dillon, chief executive of the NHS financial watchdog Nice, which has ruled Kadcyla is too expensive for NHS use, said:

Although Roche proposed a discount to the full list price of Kadcyla, it made little difference to its value for money, leaving it well above the top of our specially extended range of cost effectiveness for cancer drugs.

We are really disappointed that Roche were not able to demonstrate more flexibility to help us make a positive recommendation. The company is well aware that we could not have recommend Kadcyla at the price it proposed.

– Sir Andrew Dillon

Advertisement

National

Breast cancer drug decision 'an injustice'

The manufacturer of a breast cancer drug which has been deemed "too expensive" to be offered by the NHS has hit back at the decision.

Dr Jayson Dallas, general manager of Roche Products Limited, declared it "an incredible injustice."

Despite Roche offering a significant discount, we are once again disappointed that Nice has not shown any flexibility on access to Kadcyla.

Refusing patients access to this drug is an incredible injustice and tantamount to turning the clock back in cancer research and development. We plan to appeal this decision.

– Dr Jayson Dallas
National

NHS won't offer 'last hope' breast cancer drug

NHS
The NHS financial watchdog, Nice, has decided Kadcyla is too expensive. Credit: PA

The NHS will not offer a drug that gives patients with advanced breast cancer a last hope because it is too expensive.

Women with HER2-positive breast cancer, which has spread to other parts of their body and has not responded to initial treatment, can see their lives extended by around six months by Kadcyla.

However, the National Institute for Health and Care Excellence (Nice) has ruled that at around £90,000 per patient, the drug is too expensive to recommend for widespread use in the health service.

The NHS financial watchdog criticised Roche, who manufactures the drug, for not discounting the treatment further.

Roche said that is had offered to cut the price of the drug and will be appealing Nice's decision.

Terminal cancer sufferer condemns withdrawal of drug

A terminal cancer sufferer from Derbyshire has condemned the decision by the NHS drugs watchdog to withdraw the use of the drug Kadcyla to fight the disease on the grounds of cost.

The drug, which can add months to the life of women dying of breast cancer, costs £90,000 for a course of treatment.

The National Institute for Health and Care Excellence (Nice) said the drug was too expensive to recommend for widespread use in the health service.

Hayley Kalinins, from Borrowash, said: "How can they put a price on anybody's life?

"They do need to bring the cost of the drug down - that is obvious to everybody.

"It's been the miracle drug (for me). I've undergone four different types of chemotherapy before starting this drug.

"I've been on this drug for 18 weeks and experienced very minimal side effects from it, enabling me to have good family times with the four children."

Load more updates